SLC5A2 and hydrops fetalis: Important covariates, such as the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, which have been demonstrated to reduce HF risk (Pasternak et al., 2019), were not uniformly reported or included in the adjustment.